{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T17:13:00Z","timestamp":1656090780013},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"14_Supplement","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Activating BRAF mutations are frequent in thyroid follicular cell carcinogenesis. The BRAFV600E point mutation represents the most common oncogenic event in sporadic papillary thyroid cancer (PTC). Although at a much lower frequency the BRAFV600E mutation is also present among less differentiated, more aggressive, I131 resistant forms of thyroid cancer as poorly differentiated carcinomas (PDCs) and undifferentiated carcinomas (UCs). Small molecule inhibitors targeting either the BRAF V600E protein or upstream or downstream kinases involved in MAPK signalling are currently under pre-clinical or clinical investigation in advanced, metastatic, I131 resistant thyroid cancers. Recently, immunohistochemical (IHC) studies on PTCs, using the VE1 mouse anti-human BRAF V600E antibody have shown to be a reliable means for detecting the BRAFV600E mutation in a clinical setting without molecular genotyping units. In this study we sought to determine the usefulness of the VE1 antibody for detecting the BRAF V600E mutant protein in a series of 103 aggressive thyroid cancers (59 PDCs and 44 UCs) previously characterized by PCR-SSCP for the presence of BRAF mutations in exons 11 and 15. The BRAFV600E mutation was present in 10\/59 PDCs (17%) and 11\/44 UCs (25%). Immunohistochemistry revealed 9 mutated PDCs (sensitivity 90%) and 9 mutated UCs (82% sensitivity). The staining intensity in BRAF V600E mutated samples ranged from weak to strong. Non valuable results were found in 3 PDCs and 4 UCs. Overall the results indicate that immunohistochemistry with VE1 antibody may be an alternative to molecular biology approaches for the routine detection of BRAFV600E point mutations in clinical settings without molecular genotyping facilities. It may help clinicians in targeted therapy decision making.<\/jats:p>\n               <jats:p>Citation Format: Noa Fe\u00e1s-Rodr\u00edguez, Angela M. Costa, Tom\u00e1s Alvarez Gago, Juan Jos\u00e9 Mateos Otero, Jose Manuel Cameselle Teijeiro, Raquel Mu\u00f1oz, Ginesa Maria Garcia-Rostan. Usefulness of VE1 immunohistochemical detection of BRAFV600E in aggressive thyroid cancers (PDCs and UCs). [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4222.<\/jats:p>","DOI":"10.1158\/1538-7445.am2016-4222","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T18:02:36Z","timestamp":1469556156000},"page":"4222-4222","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Abstract 4222: Usefulness of VE1 immunohistochemical detection of BRAFV600E in aggressive thyroid cancers (PDCs and UCs)"],"prefix":"10.1158","volume":"76","author":[{"given":"Noa","family":"Fe\u00e1s-Rodr\u00edguez","sequence":"first","affiliation":[{"name":"1Institute of Molecular Biology and Genetics (IBGM), Valladolid, Spain;"}]},{"given":"Angela M.","family":"Costa","sequence":"additional","affiliation":[{"name":"2Universidade do Minho, Braga, Portugal;"}]},{"given":"Tom\u00e1s","family":"Alvarez Gago","sequence":"additional","affiliation":[{"name":"3Department of Pathology - School of Medicine - Valladolid University, Valladolid, Spain;"}]},{"given":"Juan Jos\u00e9","family":"Mateos Otero","sequence":"additional","affiliation":[{"name":"3Department of Pathology - School of Medicine - Valladolid University, Valladolid, Spain;"}]},{"given":"Jose Manuel","family":"Cameselle Teijeiro","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain."}]},{"given":"Raquel","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"1Institute of Molecular Biology and Genetics (IBGM), Valladolid, Spain;"}]},{"given":"Ginesa Maria","family":"Garcia-Rostan","sequence":"additional","affiliation":[{"name":"1Institute of Molecular Biology and Genetics (IBGM), Valladolid, Spain;"}]}],"member":"1086","container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/76\/14_Supplement\/4222\/611613\/Abstract-4222-Usefulness-of-VE1","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/76\/14_Supplement\/4222\/611613\/Abstract-4222-Usefulness-of-VE1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T16:45:00Z","timestamp":1656089100000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/76\/14_Supplement\/4222\/611613\/Abstract-4222-Usefulness-of-VE1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,15]]},"references-count":0,"journal-issue":{"issue":"14_Supplement","published-print":{"date-parts":[[2016,7,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1538-7445.am2016-4222","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,15]]}}}